The Canadian Arthritis Patient Alliance (CAPA) wrote to the federal Minister of Health to raise urgent concerns about equitable access to protein-based COVID-19 vaccines, including Nuvaxovid, for Canadians who cannot tolerate or do not wish to receive mRNA vaccines. Drawing on lived experiences from the arthritis community, CAPA outlines access barriers, communication gaps and the need to rebuild public trust through transparency, education and improved vaccine choice.

CAPA’s letter calls on federal, provincial and territorial partners to ensure sufficient supply and distribution of non-mRNA vaccine options ahead of the Fall 2026 immunization season.

Please find the full letter here.